Michael Jain: Autologous Stem Cell Boost Fuels the Fire of IEC-HS
Michael Jain, Oncologist at Moffitt Cancer Center, shared a post on X about a recent article by Snegha Ananth et al. published in Blood Advances:
“HLH (‘IEC-HS’) is hard to distinguish from CRS and other diagnoses after CAR T cells, Also, cytopenias (ICAHT) are common after CAR T and stem cell boost is the only known effective solution.
Interestingly, boost was seen to fuel the fire of IEC-HS here.”
Title: Fatal recurrence of IEC-HS after autologous stem cell boost in patients receiving BCMA-CAR T-cell therapy
Authors: Snegha Ananth, Nancy Eunice Torres, Bita Sahaf, Lekha Mikkilineni, Sebastian Fernandez-Pol, Darren Salmi, Robert Negrin, Parveen Shiraz, Melody Smith, Sushma Bharadwaj, Wen-Kai Weng, Vanessa E. Kennedy, Saurabh Dahiya, Lori Muffly, David Miklos, Matthew J. Frank, Hitomi Hosoya, Surbhi Sidana
Read the Full Article on Blood Advances
More posts featuring Michael Jain.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023